2 unknown, 1 completed, 1 not yet recruiting, 1 withdrawn. 4 Phase 1, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Unknown 2, Completed 1, Withdrawn 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Salarius Pharmaceuticals, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma SP-3164 - Lymphoma, Non-Hodgkin's, Adult | Early Phase 1 | Not yet recruiting | Salarius Pharmaceuticals, LLC | 72 | 2024-03-15 | 2023-11-22 |
| A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) Seclidemstat - Ewing Sarcoma, Myxoid Liposarcoma | Phase 1 / Phase 2 | Unknown | Salarius Pharmaceuticals, LLC | 10 | 2022-01-15 | 2023-08-01 |
| Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers SP-2577, Pembrolizumab - SCCOHT, Ovarian Clear Cell Tumor | Phase 1 | Withdrawn | HonorHealth Research Institute | 2021-12-31 | 2022-03-02 | |
| Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors SP-2577 Seclidemstat - Advanced Solid Tumors | Phase 1 | Completed | Salarius Pharmaceuticals, LLC | 23 | 2019-06-25 | 2021-10-18 |
| Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas Seclidemstat, Cyclophosphamide, Topotecan - Ewing Sarcoma, Myxoid Liposarcoma | Phase 1 | Unknown | Salarius Pharmaceuticals, LLC | 50 | 2018-06-04 | 2023-11-21 |
Chondrosarcoma, Extraskeletal Myxoid (2) · Desmoplastic Small Round Cell Tumor (2) · Histiocytoma, Angiomatoid Fibrous (2) · Liposarcoma, Myxoid (2) · Myoepithelioma (2) · Sarcoma, Clear Cell (2) · Sarcoma, Ewing (2) · Endometrial Neoplasms (1) · Fibroma (1) · Lymphoma (1) · Sarcoma (1)
Cyclophosphamide (2) · Topotecan (2) · seclidemstat (2) · pembrolizumab (1)
United States (4)